20 results
8-K
EX-2.1
ALIM
Alimera Sciences Inc.
18 May 23
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023
4:55pm
of this Agreement.
Construction. Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass
8-K
EX-10.3
ALIM
Alimera Sciences Inc.
14 Apr 21
Alimera Sciences receives $20 million
9:12am
approximate thereto;
words denoting the singular number only shall include the plural number also and vice versa;
words denoting one gender only shall
8-K
EX-10.4
0msjyya h184pc09gno6
14 Apr 21
Alimera Sciences receives $20 million
9:12am
10-K
u7hsp
25 Mar 11
Annual report
12:00am
424B4
rloost
23 Apr 10
Prospectus supplement with pricing info
12:00am
S-1
EX-10.17
pkhyp
1 Jul 08
IPO registration
12:00am
- Prev
- 1
- Next